Karyopharm Therapeutics Inc.
Karyopharm Therapeutics is a commercial-stage pharmaceutical company that discovers, develops and commercializes oral small-molecule inhibitors of XPO1 for cancer treatment. Its lead product, XPOVIO (selinexor), is marketed in the U.S. for certain adult patients with multiple myeloma and diffuse large B-cell lymphoma. In Europe and the United Kingdom, selinexor is branded NEXPOVIO and commercialized by partners. Karyopharm supports U.S. sales with representatives, nurse liaisons, a market access team and its KaryForward patient and healthcare provider support program; partners manage commercialization outside the U.S. The company is developing selinexor in clinical programs for myelofibrosis, endometrial cancer and multiple myeloma, and is developing eltanexor, a next-generation XPO1 inhibitor. It makes money from sales of XPOVIO and from licensing arrangements. Karyopharm Therapeutics is headquartered in Newton, Massachusetts.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Rodman & Renshaw downgraded Karyopharm Therapeutics from Buy to Neutral. The firm did not provide a new price target. Investors may consider this change in rating when evaluating the stock.
Rodman & Renshaw downgraded Karyopharm Therapeutics (KPTI) to Neutral and withdrew its price target after the company filed for Chapter 11 bankruptcy. Karyopharm has $328.53 million in debt and a market cap of $2.45 million, with a 89% stock decline over the past year. The company entered a restructuring agreement with lenders and noteholders, but equity holders' recovery is uncertain.
Karyopharm Therapeutics, a cancer drugmaker, filed for bankruptcy to sell itself. Ayrmid, parent of Gamida Cell, is the lead bidder. Karyopharm reported $115M in Xpovio sales, $196M in losses, and $1.8B accumulated deficit. The company aims to close the deal by early 2027, with a $55M bankruptcy loan supporting operations.
Over the past 7 days, AlphAI's AI scored 11 news stories mentioning KPTI (Karyopharm Therapeutics Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 11 bearish.
Recent KPTI coverage spans corporate actions, financial news and mergers & acquisitions.
In the last 30 days, KPTI insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($2K). The most active reporter was Abate Kristin, Chief Accounting Officer, with 1 filing.
The downgrade signals reduced confidence in near‑term performance, likely prompting short‑term selling pressure.
Equity holders face near‑zero recovery; the downgrade and bankruptcy filing will drive the stock sharply lower.
Bankruptcy sale process likely increases near-term uncertainty and credit risk, while also creating optionality if the auction yields a clean going-concern buyer.
Extension likely eases short‑term liquidity pressure but may signal ongoing financial strain.
The extension signals continued financial stress and may keep downward pressure on the stock.
AlphAI scores every news story that mentions KPTI with an AI model for sentiment and relevance, and aggregates insider trades from Karyopharm Therapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Rodman & Renshaw downgraded Karyopharm Therapeutics from Buy to Neutral. The firm did not provide a new price target. Investors may consider this change in rating when evaluating the stock.
1 min readRodman & Renshaw downgraded Karyopharm Therapeutics (KPTI) to Neutral and withdrew its price target after the company filed for Chapter 11 bankruptcy. Karyopharm has $328.53 million in debt and a market cap of $2.45 million, with a 89% stock decline over the past year. The company entered a restructuring agreement with lenders and noteholders, but equity holders' recovery is uncertain.
2 min readKaryopharm Therapeutics, a cancer drugmaker, filed for bankruptcy to sell itself. Ayrmid, parent of Gamida Cell, is the lead bidder. Karyopharm reported $115M in Xpovio sales, $196M in losses, and $1.8B accumulated deficit. The company aims to close the deal by early 2027, with a $55M bankruptcy loan supporting operations.
6 min readKaryopharm Therapeutics extended the Forbearance Period under its agreement to November 1, 2026, according to an SEC filing. The period was originally set to end earlier but was extended to this new date, absent earlier termination.
1 min readKaryopharm Therapeutics Inc. (KPTI) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. As previously disclosed in the Current Reports on Form 8-K filed by Karyopharm Therapeutics Inc. (the “Company”) on September 11, 2026 and October 14, 2026, the Company entered into a Forbearance Agreement and Limited Waiver to Indentures, dated September
1 min readKaryopharm Therapeutics (KPTI) will report Q3'26 earnings on October 29. Analysts expect $33.54M revenue and $(0.95) EPS. Details available on the company's financials page.
1 min readKaryopharm Therapeutics (KPTI) extended its forbearance period to Oct. 22, 2026, under its indenture agreement, delaying potential enforcement of defaults. The extension was agreed upon by relevant parties and follows the terms of the original agreement dated Sept. 10, 2026.
1 min readKaryopharm Therapeutics Inc. (KPTI) filed an SEC Form 8-K — Other Events. Item 8.01. Other Items. As previously disclosed in the Current Report on Form 8-K filed by Karyopharm Therapeutics Inc. (the “Company”) on September 11, 2026, the Company entered into a Forbearance Agreement and Limited Waiver to Indentures, dated September 10, 2026 (the “Forbear
1 min readKaryopharm Therapeutics Inc. (KPTI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. Forbearance Agreement On September 10, 2026, Karyopharm Therapeutics Inc. (the “Company”) and its subsidiary guarantors entered into a Forbearance Agreement and Limited Waiver to Indentures (the “Forbearance Agreement”) to pr
2 min readKaryopharm Therapeutics (KPTI) granted 1,850 RSUs to two new employees under Nasdaq Rule 5635(c)(4). The RSUs vest over three years, contingent on continued service. Karyopharm focuses on cancer therapies, with XPOVIO as its lead treatment for multiple myeloma.
1 min read
